AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

HER3 is a unique member of the EGFR family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and therapeutic resistance. U3-1402/Patritumab-GGFG...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Weining, Meng, Tao, Pu, Junyi, Ma, Linjie, Shen, Yi, Wang, Zhaohui, Pan, Rong, Wang, Mingqiao, Chen, Caiwei, Wang, Lijun, Zhang, Jianjian, Zhou, Biao, Shao, Siyuan, Qian, Yu, Liu, Shuhui, Hu, Wenhao, Meng, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477830/
https://www.ncbi.nlm.nih.gov/pubmed/37302522
http://dx.doi.org/10.1158/1535-7163.MCT-23-0198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477830/
https://www.ncbi.nlm.nih.gov/pubmed/37302522
http://dx.doi.org/10.1158/1535-7163.MCT-23-0198

Ejemplares similares